AI-generated analysis. Always verify with the original filing.
Tenon Medical, Inc. reported fourth quarter 2025 revenue of $1.5 million, up 92% from $0.8 million in Q4 2024, and full year 2025 revenue of $3.9 million, up 20% from $3.3 million in 2024, with gross margins improving to 69% in Q4 and 60% for the year. The company secured FDA 510(k) clearance for its next-generation SImmetry+ SI Joint Fusion System and completed $2.85 million ATM PIPE financing in Q4 2025.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 19, 2026, Tenon Medical, Inc., a Delaware corporation (the “Company”), issued a press release (the “Pres
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of Tenon Medical, I
| Metric | Value | Basis |
|---|---|---|
| Revenue | $1.50 | GAAP |
| Revenue | $3.90 | GAAP |
| Gross Profit | $1.00 | GAAP |
| Gross Profit | $2.40 | GAAP |
| Gross Margin | 69% | GAAP |
| Gross Margin | 60% | GAAP |
| Operating Expenses | $3.90 | GAAP |
| Operating Expenses | $15.20 | GAAP |
| Net Loss | $2.80 | GAAP |
| Net Loss | $12.60 | GAAP |
| Net Loss Per Share | $0.29 | GAAP |
| Net Loss Per Share | $1.70 | GAAP |